Post by Viopas Venture Consulting GmbH

We’re excited to invite you to the final Peak Spirit Academy session of 2025, that we are hosting on the Biotechgate platform. This time, we’re closing the year with a deep-dive into one of Europe’s most iconic biotech stories. 🗓 𝐒𝐚𝐯𝐞 𝐭𝐡𝐞 𝐝𝐚𝐭𝐞: 𝐃𝐞𝐜𝐞𝐦𝐛𝐞𝐫 11𝐭𝐡, 5𝐏𝐌 𝐂𝐄𝐓 “Biotech Must Be Bold: Lessons from the Rise, Reinvention & Acquisition of MorphoSys” Hosted by Barbara Krebs-Pohl, Managing Director at Viopas Venture Consulting GmbH Building a biotech is never linear. Discovery is hard, development is harder, and for many companies the commercial path is hardest step of all. But what does it really take to survive and adapt in today’s capital-scarce environment? Drawing on almost 3 decades at MorphoSys from scientist to Chief Business Officer, Barbara will walk us through the long growth arc of the company: early platform deals, in-/out-licensing, strategic pivots and ultimately the 2024 acquisition by Novartis. 🔥 In this session, you’ll learn: • How biotechs navigate partnership cycles: platform deals, co-development, in-licensing & creative transactions • Why portfolio focus is existential, and how MorphoSys moved across hematology, AID, oncology & more • The hidden reality of biotech survival: timelines, failed bets, capital raises & strategic pivots Barbara Krebs-Pohl is a seasoned biotech executive and trusted mentor. As CBO at MorphoSys, she led major partnerships and transactions generating $2.9bn in revenue, spearheaded the acquisition and integration of Constellation Pharmaceuticals, and served on the board of HI-Bio (acquired by Biogen). 🎙 𝐒𝐩𝐞𝐚𝐤𝐞𝐫: Dr. Barbara Krebs-Pohl 🗓 𝐃𝐚𝐭𝐞: December 11, 2025 ⏰ 𝐓𝐢𝐦𝐞: 5:00–6:00 PM CET 📩 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐡𝐞𝐫𝐞: https://lnkd.in/e2-Rs2Ni Use our promo-code for premium partnering access worth $299: viopas-BDP1225-831c2a1 Let’s close the year with a session that helps founders and investors think bolder and build companies that can survive the biotech journey!